Skip to main
VKTX
VKTX logo

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is poised for a positive outlook due to its strategic clinical updates and strong pipeline, which includes promising candidates like VK2735 and VK5211, enhancing its positioning for favorable partnership opportunities. The company's maturity relative to its peers in the independent, late-stage metabolic sector positions it well to capitalize on the growing scarcity premium as leading buyers secure assets at escalating valuations. Additionally, the anticipated clinical readouts and the innovative dosing regimens of its therapies bolster investor sentiment and expectations for Viking's future financial performance.

Bears say

Viking Therapeutics Inc. is confronted with significant industry-related risks, including the possibility of unexpected clinical trial outcomes and regulatory uncertainties that could adversely impact its product pipeline. The company's focus on metabolic and endocrine disorders may complicate its position in an increasingly price-sensitive commercial market, where competition and market dynamics are constantly evolving. Additionally, the heightened scrutiny of licensing deals, particularly in the context of US/China relations, introduces further uncertainty that could jeopardize strategic partnerships and revenue opportunities.

Viking Therapeutics (VKTX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 14 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.